BioSpace News Archive

The American Diabetes Association® is pleased to announce the opening of a new nomination window for the Pathway to Stop Diabetes® research grants in 2022.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury® (remdesivir) for the treatment of pediatric patients who are older than 28 days, weighing at least 3 kg, and are either hospitalized with COVID-19 or have mild-to-moderate COVID-19 and are considered high risk for progression to severe COVID-19, including hospitalization or death.

TeDan Surgical Innovations, leader in the development and commercialization of surgical access systems continues to address evolving surgical access techniques to the spine through the market release of the Phantom UL™ Anterior to the Psoas Surgical Access System.

MDxHealth SA, a commercial-stage precision diagnostics company, invites the holders of securities issued by the Company to its ordinary and extraordinary general shareholders’ meetings that will be held on Wednesday, 25 May 2022 at 10:00 a.m., Belgian time.

Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter 2022 earnings results after market close on Monday, May 9, 2022.

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to present and participate in 1x1 meetings at the 2022 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario on Monday, May 2, 2022 at 10:00 am ET.

CVRx, Inc. announced its financial and operating results for the first quarter of 2022.

INmune Bio announced that management will participate at the B. Riley Neuro & Ophthalmology Conference which is being held virtually on April 28, 2022.

Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced it will report financial results for the first quarter of 2022 on Monday, May 9, 2022, after market close.

Xenon Pharmaceuticals Inc., a neurology-focused biopharmaceutical company announced that Xenon’s management team will participate in the following investor conferences.